<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05086094</url>
  </required_header>
  <id_info>
    <org_study_id>BHV3241-401</org_study_id>
    <nct_id>NCT05086094</nct_id>
  </id_info>
  <brief_title>Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)</brief_title>
  <official_title>Intermediate-Size Patient Population Expanded Access Protocol of Verdiperstat in Patients With Multiple System Atrophy (MSA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Biohaven Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Biohaven Pharmaceuticals, Inc.</source>
  <brief_summary>
    <textblock>
      The purpose of this expanded access program is to provide access to the investigational drug&#xD;
      verdiperstat in patients with Multiple System Atrophy (MSA). Expanded access allows patients&#xD;
      with a serious or a life-threatening disease or condition access to an investigational drug&#xD;
      when no satisfactory approved treatment options are available.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>No longer available</overall_status>
  <study_type>Expanded Access</study_type>
  <has_expanded_access>No</has_expanded_access>
  <expanded_access_info>
    <expanded_access_type_treatment>Yes</expanded_access_type_treatment>
  </expanded_access_info>
  <condition>Multiple System Atrophy (MSA)</condition>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BHV3241, verdiperstat</intervention_name>
    <description>BHV3241/Verdiperstat 600mg BID</description>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. with a diagnosis of probable or possible MSA documented by a physician according to&#xD;
             consensus clinical criteria,5 including patients with MSA of either subtype, MSA-P or&#xD;
             MSA-C.&#xD;
&#xD;
          2. able to swallow whole tablets without crushing or chewing.&#xD;
&#xD;
          3. with established care with a physician at the specialized MSA center involved in the&#xD;
             protocol and will maintain this clinical care throughout the duration of the EAP.&#xD;
&#xD;
          4. not eligible for an ongoing clinical study with verdiperstat and/or an ongoing EAP for&#xD;
             MSA&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Based on the Physician's judgement, any condition (including history of a clinically&#xD;
             significant or unstable medical condition or lab abnormality) that would interfere&#xD;
             with the patient's ability to comply with the EAP instructions, visit schedule,&#xD;
             requirements and/or procedures, place the patient at unacceptable risk, or&#xD;
             confound/interfere with the adequate assessment/interpretation of data; including&#xD;
             difficulty swallowing verdiperstat tablets or any other sound medical, psychiatric&#xD;
             and/or social reason.&#xD;
&#xD;
          2. Presence of clinically significant thyroid disease despite treatment and/or TSH &gt;10&#xD;
             mIU/ L at Screening/Baseline, confirmed by repeat.&#xD;
&#xD;
          3. Patient is known to have acute or chronic liver disease that is clinically significant&#xD;
             in the Prescriber's judgment&#xD;
&#xD;
          4. First or second dose of COVID-19 vaccination within 7 days of first dose of&#xD;
             verdiperstat.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Morrisville</city>
        <state>North Carolina</state>
        <zip>27560</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>October 8, 2021</study_first_submitted>
  <study_first_submitted_qc>October 8, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">October 20, 2021</study_first_posted>
  <last_update_submitted>October 8, 2021</last_update_submitted>
  <last_update_submitted_qc>October 8, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 20, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Multiple System Atrophy</keyword>
  <keyword>MSA</keyword>
  <keyword>verdiperstat</keyword>
  <keyword>BHV3241</keyword>
  <keyword>MPO inhibitor</keyword>
  <keyword>Myeloperoxidase inhibitor</keyword>
  <keyword>MSA-P</keyword>
  <keyword>MSA-C</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Multiple System Atrophy</mesh_term>
    <mesh_term>Shy-Drager Syndrome</mesh_term>
    <mesh_term>Atrophy</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

